title: Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis.
abstract: At present only few biological data are available to indicate whether psoriatic arthritis (PsA) is part of the spondyloarthropathy (SpA) concept, whether it is a separate disease entity or a heterogeneous disease group with oligoarticular/axial forms belonging to SpA and polyarticular forms resembling rheumatoid arthritis (RA). To address this issue with regard to peripheral synovitis, we compared the synovial characteristics of PsA with those of ankylosing spondylitis (AS)/undifferentiated SpA (USpA) and RA, and compared the synovium of oligoarticular versus polyarticular PsA. Synovial biopsies were obtained from patients with RA, nonpsoriatic SpA (AS + USpA), and oligoarticular and polyarticular PsA. The histological analysis included examination(s) of the lining layer thickness, vascularity, cellular infiltration, lymphoid aggregates, plasma cells and neutrophils. Also, we performed immunohistochemical assessments of CD3, CD4, CD8, CD20, CD38, CD138, CD68, CD163, CD83, CD1a, CD146, alphaVbeta3, E-selectin, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, S100A12, intracellular citrullinated proteins and major histocompatibility complex (MHC)-human cartilage (HC) gp39 peptide complexes. Comparing SpA (PsA + AS + USpA) with RA, vascularity, and neutrophil and CD163+ macrophage counts were greater in SpA (P < 0.05), whereas lining layer thickness and the number of CD83+ dendritic cells were greater in RA (P < 0.05). In RA, 44% of samples exhibited positive staining for intracellular citrullinated proteins and 46% for MHC-HC gp39 peptide complexes, whereas no staining for these markers was observed in SpA samples. We excluded influences of disease-modifying antirheumatic drug and/or corticosteroid treatment by conducting systematic analyses of treated and untreated subgroups. Focusing on PsA, no significant differences were observed between PsA and nonpsoriatic SpA. In contrast, vascularity (P < 0.001) and neutrophils were increased in PsA as compared with RA (P = 0.010), whereas staining for intracellular citrullinated proteins and MHC-HC gp39 peptide complexes was exclusively observed in RA (both P = 0.001), indicating that the same discriminating features are found in PsA and other SpA subtypes compared with RA. Exploring synovial histopathology between oligoarticular and polyarticular PsA, no significant differences were noted. Moreover, intracellular citrullinated proteins and MHC-HC gp39 peptide complexes, which are specific markers for RA, were observed in neither oligoarticular nor polyarticular PsA. Taken together, these data indicate that the synovial histopathology of PsA, either oligoarticular or polyarticular, resembles that of other SpA subtypes, whereas both groups can be differentiated from RA on the basis of these same synovial features, suggesting that peripheral synovitis in PsA belongs to the SpA concept.
authors.affiliation: Department of Rheumatology, Ghent University Hospital, Ghent, Belgium. elli.kruithof@ugent.be
authors.forename: Elli
authors.initials: E
authors.lastname: Kruithof
authors.forename: Dominique
authors.initials: D
authors.lastname: Baeten
authors.forename: Leen
authors.initials: L
authors.lastname: De Rycke
authors.forename: Bernard
authors.initials: B
authors.lastname: Vandooren
authors.forename: Dirk
authors.initials: D
authors.lastname: Foell
authors.forename: Johannes
authors.initials: J
authors.lastname: Roth
authors.forename: Juan D
authors.initials: JD
authors.lastname: Cañete
authors.forename: Annemieke M
authors.initials: AM
authors.lastname: Boots
authors.forename: Eric M
authors.initials: EM
authors.lastname: Veys
authors.forename: Filip
authors.initials: F
authors.lastname: De Keyser
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009418:S100 Proteins / Q000096:biosynthesis; D000067616:S100A12 Protein; D025242:Spondylarthropathies / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D013583:Synovial Membrane / Q000378:metabolism / Q000473:pathology*; D013585:Synovitis / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology
chemical_list: D018501:Antirheumatic Agents; D009418:S100 Proteins; D000067616:S100A12 Protein; C090441:S100A12 protein, human